Cue Biopharma (NASDAQ:CUE) VP Michael Vincent Meluzio Sells 1,144 Shares of Company Stock

Cue Biopharma, Inc. (NASDAQ:CUE) VP Michael Vincent Meluzio sold 1,144 shares of the firm’s stock in a transaction that occurred on Monday, October 12th. The shares were sold at an average price of $28.05, for a total value of $32,089.20. Following the completion of the sale, the vice president directly owned 47,817 shares of the company’s stock, valued at approximately $1,341,266.85. The trade was a 2.34% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Michael Vincent Meluzio also recently made the following trade(s):

• On Thursday, August 13th, Michael Vincent Meluzio sold 5,628 shares of Cue Biopharma stock. The stock was sold at an average price of $30.09, for a total value of $169,346.52.

Cue Biopharma Stock Performance

CUE traded down $0.97 during trading hours on Wednesday, reaching $18.60. The company’s stock had a trading volume of 244,958 shares, compared to its average volume of 475,854. Cue Biopharma, Inc. has a 52 week low of $4.97 and a 52 week high of $45.50. The company’s 50-day moving average is $27.73 and its 200-day moving average is $72.25. The firm has a market cap of $135.04 million, a PE ratio of -0.69 and a beta of 2.62.

Cue Biopharma (NASDAQ:CUE) last announced its quarterly earnings results on Friday, August 14th. The company reported ($24.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.69) by ($22.45). Cue Biopharma had a negative net margin of 435.83% and a negative return on equity of 620.06%. The business had revenue of $7.88 million for the quarter, compared to analyst estimates of $3.00 million. Equities analysts anticipate that Cue Biopharma, Inc. will post -21.79 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms recently weighed in on CUE. Wall Street Zen cut Cue Biopharma from a “sell” rating to a “strong sell” rating in a report on Saturday, September 26th. Zacks Research raised Cue Biopharma to a “hold” rating in a report on Monday, September 21st. B. Riley Financial began coverage on Cue Biopharma in a report on Friday, September 18th. They issued a “buy” rating and a $83.00 price objective on the stock. Finally, Weiss Ratings cut Cue Biopharma from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, August 27th. One research analyst has rated the stock with a Strong Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Cue Biopharma currently has an average rating of “Hold” and a consensus target price of $83.00.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in CUE. Citadel Advisors LLC increased its holdings in shares of Cue Biopharma by 301.8% during the second quarter. Citadel Advisors LLC now owns 25,633 shares of the company’s stock worth $809,000 after purchasing an additional 38,333 shares during the period. Seven Fleet Capital Management LP bought a new stake in shares of Cue Biopharma in the second quarter valued at approximately $338,000. Bank of America Corp DE bought a new stake in shares of Cue Biopharma in the second quarter valued at approximately $219,000. ADAR1 Capital Management LLC bought a new stake in shares of Cue Biopharma in the second quarter valued at approximately $1,742,000. Finally, Northwestern Mutual Wealth Management Co. acquired a new stake in Cue Biopharma during the second quarter worth approximately $83,000. Institutional investors and hedge funds own 35.04% of the company’s stock.

About Cue Biopharma

Cue Biopharma, Inc is a clinical-stage biotechnology company focused on developing targeted immunotherapies for cancer and other serious diseases. The company’s approach is based on its proprietary Immuno-STAT (Selective Targeting of Antigenic T cells) platform, which is designed to selectively activate and expand disease-specific T cells in the body while potentially reducing the broad immune activation associated with some conventional immunotherapies.

Cue Biopharma’s pipeline includes biologic product candidates intended to target cancer-associated antigens.